Intellia Therapeutics Inc(NTLA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 7:22 PM ET (Korea 10/27 08:22)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.36 | Insider Own | 4.41% | Shs Outstand | 140.0M | Perf Week | -2.76% |
| Market Cap | 1.58B | Forward P/E | - | EPS next Y | 17.9% | Insider Trans | -0.64% | Shs Float | 133.9M | Perf Month | -4.17% |
| Enterprise Value | 1.21B | PEG | - | EPS next Q | -0.8 | Inst Own | 99.66% | Short Float | 33.68% | Perf Quarter | 3.4% |
| Income | -0.40B | P/S | 26.51 | EPS this Y | 16.05% | Inst Trans | 30.26% | Short Ratio | 10.41 | Perf Half Y | -13.65% |
| Sales | 0.06B | P/B | 2.17 | EPS next 5Y | 24.19% | ROA | -45.55% | Short Interest | 45.11M | Perf YTD | 25.25% |
| Book/sh | 5.2 | P/C | 3.6 | EPS past 3/5Y | 14.82% -9.7% | ROE | -55.44% | 52W High | -57.27% ($26.35) | Perf Year | -56.02% |
| Cash/sh | 3.12 | P/FCF | - | Sales past 3/5Y | 9.09% 3.13% | ROIC | -51.43% | 52W Low | 41.64% ($7.95) | Perf 3Y | -54.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.42% | Gross Margin | 74.37% | Volatility(W/M) | 5.55% 6.27% | Perf 5Y | -91.47% |
| Dividend TTM | - | EV/Sales | 20.39 | Sales Y/Y TTM | 12.58% | Oper. Margin | -711.66% | ATR (14) | 0.7 | Perf 10Y | -20.54% |
| Dividend Ex-Date | - | Quick Ratio | 6.65 | EPS Q/Q | 18.15% | Profit Margin | -672.16% | RSI (14) | 42.44 | Recom | 2.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.65 | Sales Q/Q | -46.23% | SMA20 | -5.52% ($11.92) | Beta | 1.85 | Target Price | $22.88 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/8/6 | SMA50 | -7.67% ($12.2) | Rel Volume | 0.48 | Prev Close | $11.21 |
| Employees | 377 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -0.09% -40.99% | SMA200 | -13.73% ($13.05) | Avg Volume(3M) | 4.33M | Price | $11.26 |
| IPO | 2016/5/6 | Option/Short | Yes/Yes | Trades | 13204 | Volume | 2,064,702 | Change | 0.45% |
🧬 This is a US clinical-stage biotech company developing therapeutics using gene editing technology. The company uses CRISPR gene editing technology to develop treatments that directly correct genes inside the body, and holds pipeline candidates targeting rare genetic diseases and autoimmune diseases, among others. It has established itself as a differentiated gene editing biotech with an in vivo gene editing approach.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
NTLA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +16.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,651. Peers typically go for $1,213.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
33.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #120 of 594 in the industry
Based on market cap of $2B.
NUVB#117 Nuvation Bio Inc $2B PER - 
RARE#118 Ultragenyx Pharmaceutical Inc $2B PER - 
GENB#119 Generate Biomedicines Inc $2B PER - NTLA#120 Intellia Therapeutics Inc $2B PER - 
TRAX#121 First Tracks Biotherapeutics Inc $2B PER - 
FAQ
What kind of company is NTLA?
NTLA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NTLA?
The market cap of NTLA is approximately $1.6B, ranking 2,231 within its sector.
What is the 52-week high and low for NTLA?
NTLA has recorded a 52-week high of $26.35 and a low of $7.95.
